The study suggests that patients who previously had a case of C-diff and receive gastric acid suppressants may be at increased risk of C-diff recurrence. Sahil Khanna, a gastroenterologist at US-based non-profit Mayo Clinic said, “The study found that use of gastric acid suppression medications are associated with a statistically significant increased risk of development of recurrent C-diff in patients with a prior episode of C-diff”. For the study, the team conducted a systematic review and meta-analysis of 16 studies with 7,703 patients with C-diff and 1,525 of these developed recurrent C-diff. The researchers analysed gastric suppression medications including proton pump inhibitors, such as omeprazole, and histamine 2 blockers, such as ranitidine, which are commonly prescribed and consumed over-the-counter medications for gastroesophageal reflux disease, peptic ulcer disease or dyspepsia. The results showed that the rate of recurrent C-diff in patients with gastric suppression was 22.1 per cent, compared to 17.3 per cent in patients without gastric acid suppression. Thus, “it may be reasonable to re-evaluate the need for these medications in patients with C-diff,” Khanna noted.